Mobidiag Oy, an Espoo, Finland-based molecular diagnostics company, signed a €15m loan with the European Investment Bank Group.
As part of the InnovFin initiative, the loan will allow Mobidiag to finalize and scale up Novodiag® products manufacturing, assay validation and commercialization over the next 3 years. The operation is supported by “InnovFin – EU Finance for Innovators”, with the financial backing of the European Union under Horizon 2020 Financial Instruments.
Led by Tuomas Tenkanen, CEO, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases serving the European clinical diagnostics market including:
– The Amplidiag® product line, innovative multiplex tests for gastrointestinal infections;
– The new Amplidiag® Easy platform that automates the workflow from sample to results; and
– The Novodiag® platform and associated panels (upcoming), an automated solution suitable for smaller volumes and labs.
The company has a subsidiary in Paris, France.